Plain-English translation of NCT05416775 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new approach to treating advanced non-small cell lung cancer by combining SHR-8068 and adebrelimab—two medications that work with your immune system—either alone or together with standard chemotherapy. The study wants to learn whether these combinations are safe and whether they help shrink tumors and extend survival in patients whose cancer has progressed or returned after previous treatments.
Advanced lung cancer is very difficult to treat once it has stopped responding to standard therapies. This medication represents a new approach using the body's own immune system, and researchers want to see if combining these newer immunotherapies with traditional chemotherapy works better and is safe enough for patients to tolerate.
You would receive the study medications either as injections or infusions, likely on a regular schedule at a clinic. Depending on which treatment group you are assigned to, you might receive the new medications alone or combined with standard chemotherapy. You would have regular clinic visits for blood work, scans to measure your tumors, and check-ups to monitor for side effects. The trial will last several months to over a year depending on how well you respond.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China